



TCR² Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Cambridge, MA, August 29, 2017 – TCR² Therapeutics Inc. announced today that its Chief Scientific Officer Robert Hofmeister, PhD, and Scientific Founder Patrick Baeuerle, PhD, have been invited to speak at the CAR-TCR Summit and the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference being held next week in Boston, MA, and Mainz/Frankfurt, Germany, respectively.

“The T cell therapy field is moving beyond CARs toward TCR-based approaches for tackling solid tumors. There is a growing realization that we may need to engage the entire T cell receptor complex to trigger the full signaling events that drive important processes such as robust activation, persistence and migration,” said Garry Menzel, PhD, Chief Executive Officer. “TCR² is at the forefront of this next wave with our unique TRuC™ platform in preclinical development for mesothelin-positive solid tumors.”

The oral presentations will discuss rationales and mechanisms for its MHC-independent TRuC™-T cells and provide additional preclinical data for TC-210, the company’s lead program targeting mesothelin-positive solid tumors including ovarian, pancreatic, mesothelioma and lung cancers. TC-210 demonstrated superior antitumor activity and durability compared to CAR-T cells in a preclinical mesothelioma model and showed potential safety benefits based on its cytokine release profile.

Presentation at CAR-TCR Summit 2017

- **Title:** TRuC™-T Cells: A New Class of Engineered T Cells for Solid Tumor Therapy
- **Session Title:** CAR-TCR Translation Stream
- **Date & Time:** Wednesday September 6, 2017 from 2:25pm-2:55pm EDT
- **Location:** Seaport Hotel and World Trade Center in Boston, MA
- **Presenter:** Robert Hofmeister, PhD, Chief Scientific Officer

Presentation at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

- **Title:** TRuC™-T Cells Targeting CD19 or Mesothelin Demonstrate Superior Antitumor Activity in Preclinical Models Compared to CAR-T Cells
- **Session Title:** Novel Agents
- **Date & Time:** Thursday September 7, 2017 from 1:00pm-3:00pm CEST
- **Location:** Rheingoldhalle Congress Center in Mainz/Frankfurt, Germany
- **Presenter:** Patrick Baeuerle, PhD, Founder

About TCR² Therapeutics

TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a \$44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

Media Contact:

Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com

###